Caliway Wins US FDA Clearance to Advance Phase 3b Trial of Fat-Reduction Drug
() -- Caliway Biopharmaceuticals (TPE:6919) said the U.S. Food and Drug Administration has completed its 30-day review of an investigational new drug application for a Phase 3b study of CBL-514, allowing the trial to proceed. CBL-514 is an injectable treatment for reducing abdominal fat, according to a Friday Taiwan Ex